SynthesisBioMed research international2019
Lipoprotein-Associated Phospholipase A2 Activity and Mass as Independent Risk Factor of Stroke: A Meta-Analysis.
Synthesis in BioMed research international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- The association between dietary patterns and the novel inflammatory markers platelet-activating factor and lipoprotein-associated phospholipase A2: a systematic review.Nutrition reviews · 2022Pooled it
- The Role of Biomarkers in Atherothrombotic Stroke-A Systematic Review.International journal of molecular sciences · 2021Pooled it
- Diabetes status modifies the long-term effect of lipoprotein-associated phospholipase A2 on major coronary events.Diabetologia · 2022Trial
- Associations between healthy food groups and platelet-activating factor, lipoprotein-associated phospholipase AEuropean journal of nutrition · 2024Article
- China stroke surveillance report 2021.Military Medical Research · 2023Review
- Correlation of lipoprotein-associated phospholipase A2 and cerebral microbleeds in patients with acute ischaemic stroke.BMC neurology · 2022Article
- Neurological aspects of SARS-CoV-2 infection: lipoproteins and exosomes as Trojan horses.Trends in endocrinology and metabolism: TEM · 2022Review
- Serum levels of sLOX-1 and Lp-PLA2 can predict the prognosis of acute cerebral infarction with a high specificity.Physiological reports · 2022Observational
- Biogenic Phytochemicals Modulating Obesity: From Molecular Mechanism to Preventive and Therapeutic Approaches.Evidence-based complementary and alternative medicine : eCAM · 2022Review
- Association Lp-PLA2 Gene Polymorphisms with Coronary Heart Disease.Disease markers · 2022Article
- Elevated Lipoprotein-Associated Phospholipase A2 Is Associated With Intracranial Atherosclerosis.Frontiers in neurology · 2022Article
- Right Atrial Fluorodeoxyglucose Uptake Is a Risk Factor for Stroke and Improves Prediction of Stroke Above the CHAFrontiers in cardiovascular medicine · 2022Article
- Biological Properties and Clinical Significance of Lipoprotein-Associated Phospholipase ACardiovascular therapeutics · 2022Review
- Hypothesis of "stroke-stop" formula: a tool for risk index determination in development of acute cerebrovascular disease in asymptomatic individuals with carotid stenosis.BMC neurology · 2021Article
- Correlation between Serum LP-PLA2 and sST2 Levels and the Condition of Patients with Acute Heart Failure and Their Prognostic Value.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- An analysis of the correlation between the human apolipoprotein E gene polymorphism and lipoprotein-associated phospholipase A2.Cardiovascular diagnosis and therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe association between lipoprotein-associated phospholipase A2 (Lp-PLA2) and stroke risk is inconsistent. We conducted a meta-analysis to determine whether elevated Lp-PLA2 is a risk factor for stroke.
methodsStudies were included if they reported Lp-PLA2 mass and/or activity levels and adjusted risk estimates of stroke. The primary outcome was overall stroke incidence. The combined results were shown as relative risks (RRs) with 95% confidence intervals (CI) for per 1 standard deviation (SD) higher value of Lp-PLA2 and the highest versus lowest Lp-PLA2 category.
resultsTwenty-two studies involving 157,693 participants were included for analysis. After adjusting for conventional risk factors, the RRs for overall stroke with 1 SD higher Lp-PLA2 activity and mass were 1.07 (95% CI 1.02-1.13) and 1.11 (95% CI 1.04-1.19), respectively. The RRs of ischemic stroke with 1 SD higher Lp-PLA2 activity and mass were 1.08 (95% CI 1.01-1.15) and 1.11 (95% CI 1.02-1.22), respectively. When comparing the highest and lowest levels of Lp-PLA2, the RRs of stroke for Lp-PLA2 activity and mass were 1.26 (95% CI 1.03-1.54) and 1.56 (95% CI 1.21-2.00), respectively. Finally, when comparing the highest and lowest levels of Lp-PLA2, the pooled RRs of ischemic stroke for Lp-PLA2 activity and mass were 1.29 (95% CI 1.07-1.56) and 1.68 (95% CI 1.12-2.53), respectively.
conclusionsElevated baseline Lp-PLA2 levels, detected either by activity or mass, are associated with increased stroke risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.